Project Details
Projekt Print View

GSC 270:  International Graduate School in Molecular Medicine Ulm

Subject Area Medicine
Term from 2007 to 2019
Project identifier Deutsche Forschungsgemeinschaft (DFG) - Project number 53244728
 
Final Report Year 2019

Final Report Abstract

Ulm University founded the International Graduate School in Molecular Medicine Ulm (IGradU) in 2006 to provide high-quality postgraduate training. IGradU has been supported by the Excellence Initiative since 2007. The goal of IGradU was, and still is, to introduce doctoral candidates at Ulm University conducting research in the field of biomedicine to a structured postgraduate programme. Key research areas cover neurobiology, ageing & degeneration, oncology & endocrinology, virology, microbiology & biotechnology, systems biology, development & regeneration as well as trauma research and immune modulation. There are two structured training programmes on offer: the International PhD Programme in Molecular Medicine for doctoral candidates in natural sciences and the Experimental Medicine programme for doctoral candidates in medicine. As of 31 July 2019, 272 candidates have completed the PhD programme and 156 are enrolled. IGradU is run by a board, which in turn is advised by an international advisory committee. The International PhD Programme in Molecular Medicine offers a three-year structured doctorate including two intermediate evaluations. Admission regulations stipulate clear criteria for selection. During their postgraduate course, doctoral candidates are monitored by a Thesis Advisory Committee (TAC) made up of three supervisors. Graduates opt to receive either the international academic title of PhD or the German academic title Dr. rer. nat. In order to combat deficiencies in the supervision and quality of medical theses, the Medical Faculty implemented the structured training programme Experimental Medicine in 2005, which was subsequently adopted by IGradU in 2010. The Experimental Medicine programme is defined as a first step in the training of clinician scientists. The entry requirement for the programme is an above-average intermediate examination (part one of the national medical licensing exam). Doctoral candidates must interrupt their studies in medicine for nine months to concentrate fully on their experimental work. Doctoral candidates present their research in the programme's seminars and present up-to-date scientific literature in a Journal Club. A Junior Faculty was established during the second funding period. Young researchers who receive third-party funding for PhD students but are not yet allowed to be first supervisor due to the lack of a higher qualification (Habilitation) are organized within this group of scientists. Within IGradU, members of the Junior Faculty will be allowed to participate in TACs. Members of the Junior Faculty will be trained for their future career by providing additional training opportunities that concentrate on (i) academia; (ii) industry; or (iii) strengthening the training of clinician scientists. 2 Finally, IGradU served as a role model for the implementation of the Graduate & Professional Training Center Ulm (ProTrainU) that provides support for young scientist at the level of Ulm University.

Link to the final report

https://dx.doi.org/10.2314/KXP:1698163444

Publications

 
 

Additional Information

Textvergrößerung und Kontrastanpassung